| Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. Co. has developed a proprietary product engine, FulcrumSeek, that it employs to systematically identify and validate cellular drug targets. Co.' products include: losmapimod, a small molecule that it is developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive and disabling disorder characterized by muscle degeneration and fat infiltration; and FTX-6058, an investigational oral fetal hemoglobin, inducer that is in development for sickle cell disease and select other hemoglobinopathies, including ß-thalassemia. We show 16 historical shares outstanding datapoints in our coverage of FULC's shares outstanding history.|
Understanding the changing numbers of FULC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like FULC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching FULC by allowing them to research FULC shares outstanding history
as well as any other stock in our coverage universe.